I
Ideaya Biosciences Inc (IDYA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$30.36
-1.47 (-4.62%)
Market Cap: $3.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ideaya Biosciences Inc (IDYA) Valuation Multiples
Ideaya Biosciences (IDYA) trades at 85.5x sales and 2.9x book value. Its P/S of 85.5x is above its 5-year median of 20.9x. Its forward P/E is 4.7x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 4.7x |
| Price to sales | 85.5x |
| Price to book | 2.9x |
| PEG | N/A |
| FCF yield | -11.2% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 85.5x | 20.9x | N/A |
| P/B | 2.9x | 2.6x | N/A |
Valuation History
Over the 6 of the 7 year ends shown that have a P/S, its P/S ranged from 14.0x in 2025 to 320.7x in 2024. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $34.57 | 14.0x | 3.0x |
| 2024 | $25.70 | 320.7x | 2.1x |
| 2023 | $35.58 | 84.7x | 3.7x |
| 2022 | $18.17 | 14.4x | 2.5x |
| 2021 | $23.64 | 29.2x | 3.0x |
| 2020 | $14.00 | 20.6x | 2.1x |
| 2019 | $7.50 | N/A | 1.5x |
Frequently Asked Questions About IDYA
What is IDYA's forward P/E ratio?
Ideaya Biosciences has a forward P/E ratio of 4.7x.
What is IDYA's price to sales ratio?
Ideaya Biosciences has a price to sales ratio of 85.5x.
IDYA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors